Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 787-792

  Kita, Aya ^a   Nakahara, Takahito ^a   Yamanaka, Kentaro ^a   Nakano, Kenji ^a   Nakata, Mari ^a   Mori, Masamichi ^a   Kaneko, Naoki ^a   Koutoku, Hiroshi ^a   Izumisawa, Nobuyuki ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Aggressive non Hodgkin lymphoma; Apoptosis; Immunohistochemical analysis; Survivin; Xenograft model; YM155

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; ANTILEUKEMIC AGENT; RITUXIMAB; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MALE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOMA, NON-HODGKIN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NAPHTHOQUINONES; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955612819     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.016     Document Type: Article

References (34)

1. Armitage J.O. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1023-1030.
2. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
3. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
4. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
5. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
6. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
7. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58:5315-5320.
8. O'Connor D.S., Grossman D., Plescia J., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000, 97:13103-13107.
9. Lu C.D., Altieri D.C., Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998, 58:1808-1812.
10. Fukuda S., Pelus L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001, 98:2091-2100.
11. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., Altieri D.C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351:882-883.
12. Monzo M., Rosell R., Felip E., et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999, 17:2100-2104.
13. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000, 6:127-134.
14. Satoh K., Kaneko K., Hirota M., Masamune A., Satoh A., Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001, 23:251-258.
15. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998, 58:5071-5074.
16. Chakravarti A., Noll E., Black P.M., et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002, 20:1063-1068.
17. Kappler M., Bache M., Bartel F., et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004, 11:186-193.
18. Islam A., Kageyama H., Takada N., et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
19. Grossman D., McNiff J.M., Li F., Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999, 113:1076-1081.
20. Shinohara E.T., Gonzalez A., Massion P.P., et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005, 103:1685-1692.
21. Krajewska M., Krajewski S., Banares S., et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003, 9:4914-4925.
22. Schlette E.J., Medeiros L.J., Goy A., Lai R., Rassidakis G.Z. Survivin expression predicts poorer prognosis in anaplastic large cell lymphoma. J Clin Oncol 2004, 22:1682-1688.
23. Martinez A., Bellosillo B., Bosch F., et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004, 164:501-510.
24. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006, 18:609-615.
25. Nakahara T., Takeuchi M., Kinoyama I., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021.
26. Zaffaroni N., Daidone M.G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Update 2002, 5:65-72.
27. Iwasa T., Okamoto I., Suzuki M., et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008, 14:6496-6504.
28. Tolcher A.W., Mita A., Lewis L.D., et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008, 26:5198-5203.
29. Monks A., Scudiero D., Skehan P., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991, 83:757-766.
30. Flavell D.J., Boehm D.A., Emery L., Noss A., Ramsay A., Flavell S.U. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used alone in combination than with either immunotoxin alone. Int J Cancer 1995, 62:337-344.
31. Flavell D.J., Noss A., Pulford K.A., Ling N., Flavell S.U. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 1997, 57:4824-4829.
32. DiJoseph J.F., Goad M.E., Dougher M.M., et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004, 10:8620-8629.
33. Ansell S.M., Arendt B.K., Grote D.M., et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004, 18:616-623.
34. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007, 26:3603-3636.